Skip to main content

Advertisement

Table 1 Overall and group demographic and clinical data at study entry

From: Mortality in dialysis patients may not be associated with ESA dose: a 2-year prospective observational study

  Overall NE LE GR HE PR
Age, years * 60 ± 14 53 ± 14 57 ± 14 60 ± 15 64 ±12 69 ± 11
Females, n (%) 109 (36.1) 6 (17.1) 16 (33.3) 61 (38.1) 17 (41.5) 9 (50)
Diabetes, n (%) 56 (18.5) 7 (20.0) 15 (31.0) 23 (14.3) 8 (16.3) 3 (16.7)
CAD, n (%) 108 (35.8) 9 (25.7) 17 (35.4) 56 (35) 18 (43.9) 8 (44.4)
HT, n (%) * 267 (88.4) 26 (74.3) 44 (91.7) 146 (91.3) 34 (82.9) 17 (94.4)
PVD, n (%) 70 (23.3) 4 (11.4) 16 (33.3) 33 (20.6) 11 (26.8) 6 (33.3)
CVA, n (%) * 38 (12.7) 2 (5.7) 6 (12.5) 17 (10.6) 12 (29.3) 1 (5.6)
COPD, n (%) 29 (9.6) 4 (11.4) 3 (6.3) 13 (8.1) 7 (17.1) 2 (11.1)
Dyslipidemia, n (%) 118 (39.1) 8 (22.9) 24 (50) 60 (37.5) 17 (41.5) 9 (50)
BMI kg/m 2 * 25.9 ± 5.6 27.1 ± 7.7 27.5 ± 5.9 25.1 ± 4.7 24.6 ± 4.4 28.9 ± 6.9
Obesity, n (%) * 18 (6) 3 (8.6) 6 (12.5) 6 (3.8) 0 3 (16.7)
Previous transplant, n (%)* 10 (28.6) 4 (8.3) 19 (11.9) 5 (12.2) 1 (5.6) 39 (12.9)
HD, n (%) * 244 (80.8) 24 (68.6) 30 (62.5) 135 (84.4) 38 (92.7) 17 (94.4)
Duration of ESKD (months) 34 (18–60) 49 (28–111) 26 (15–56) 34 (17–60) 31 (19–54) 31 (23–58)
Time on dialysis (months) 33 (18–58) 41 (27–88) 36 (18–66) 37 (22–59) 31 (23–58) 35 (18–61)
  1. BMI: body mass index, CAD: coronary artery disease, HT: hypertension, PVD: peripheral vascular disease, CVA: past cerebrovascular accident, COPD: chronic obstructive pulmonary disease, Obesity: BMI > 30 kg/m2, HD: haemodialysis, ESKD: end stage kidney disease *: p < 0.05 for between-group analysis. Data are displayed as mean ± SD, n (%), or median (25th-75th quartile), as indicated.